-
Innovation Ranking
NewInnovation Ranking – Krystal Biotech Inc
Krystal Biotech Inc (Krystal Biotech) is a gene therapy company that develops and commercializes treatments for dermatological diseases. The company’s pipeline includes B-VEC (bercolagene telserpavec) gene therapy, against dystrophic epidermolysis bullosa (DEB), KB105 therapy, targeting autosomal recessive congenital ichthyosis (ARCI), a genetic skin disease caused due to deficiency of TGM1 gene. Krystal Biotech also investigating KB301, to treat aesthetic skin conditions, KB104, against Netherton Syndrome, KB407, for the treatment of Junctional Epidermolysis Bullosa (JEB) and KB5XX, targeting chronic skin diseases....
-
Product Insights
NewNet Present Value Model: Krystal Biotech Inc’s Beremagene geperpavec
Empower your strategies with our Net Present Value Model: Krystal Biotech Inc's Beremagene geperpavec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Krystal Biotech Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Krystal Biotech Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-707 in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-707 in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-707 in Osteosarcoma Drug Details: KB-707 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-707 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-707 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-707 in Non-Small Cell Lung Cancer Drug Details: KB-707...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-707 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-707 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-707 in Metastatic Melanoma Drug Details: KB-707 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-707 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-707 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-707 in Solid Tumor Drug Details: KB-707 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-408 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: KB-408 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vemurafenib in Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vemurafenib in Thyroid Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vemurafenib in Thyroid Cancer Drug Details: Vemurafenib (Zelboraf, RG7204, PLX4032, RO5185426)...
-
Product Insights
Congenital Ichthyosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Ichthyosis - Drugs In Development, 2023’, provides an overview of the Congenital Ichthyosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Ichthyosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...